Roche's (RHHBY) Sparks Set to Develop Gene Therapy for HD
Roche's (RHHBY) Sparks enters into a collaboration agreement with NeuExcell Therapeutics to develop a novel gene therapy for HD.
Roche RHHBY announced that one of its member companies, Sparks Therapeutics, has entered into a research collaboration agreement with NeuExcell Therapeutics to co-develop a novel gene therapy for Huntington's Disease (“HD”), a brain disorder.
Please note that while the therapy for HD will be developed using NeuExcell's proprietary neuro-regenerative gene therapy platform, Sparks will further advance the research using its proprietary adeno-associated virus vector platform.
Roche’s stock has rallied 13.5% so far this year in comparison with the industry’s 15.6% rally.
Image Source: Zacks Investment Research
Per the agreement terms, NeuExcell will be eligible to receive potential milestone payments upto $190 million along with product royalties. Sparks has the option to license the worldwide rights to the therapy.
HD is a genetic brain disorder that impacts the abilities of movement, behavior and cognition. The complications associated with HD are usually fatal. Currently, there is no cure for HD.
Per the companies, since neurons cannot regenerate themselves or be replaced, the existing treatments for brain disorder focus on slowing the disease progression. NeuExcell’s proprietary platform seeks to reprogram endogenous glial cells to regenerate new neurons at the site of the injury.
We inform members that Roche has also licensed tominersen, another candidate for HD indication, from Ionis Pharmaceuticals IONS. In March 2021, Roche discontinued the phase III study evaluating tominersen, in manifest HD based on results of a pre-planned review of data from the phase III GENERATION HD1 study, conducted by Independent Data Monitoring Committee. The candidate is currently being evaluated in two different clinical studies.
Zacks Rank & Stocks to Consider
Roche currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the biotech sector include Regeneron Pharmaceuticals REGN and Vertex Pharmaceuticals VRTX, each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings per share estimates for 2021 have increased from $49.96 to $54.15 in the past 30 days. The same for 2022 has risen from $40.91 to $44.11 over the same period. The stock has rallied 40.7% in the year so far.
Vertex’s earnings per share estimates for 2021 have increased from $12.28 to $12.37 in the past 30 days. The same for 2022 has risen from $13.02 to $13.13 over the same period.
Zacks' Top Picks to Cash in on Artificial Intelligence
In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report
Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research